EGFR and non-small cell lung carcinoma: Several phase III trials comparing EGFR-TKIs and platinum combination therapy in patients with EGFR-mutated NSCLC had been reported, and in all of these trials, the EGFR-TKIs groups had significantly better results in term of progression-free survival (PFS) [5–7].